Aspira Women’s Health Inc. income statement AWHL

Annual Quarterly

In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, Aspira Women’s Health Inc. reported revenue of $2.0 million, down 14.9% from the same quarter a year earlier. It recorded a net loss of $2.4 million. The operating loss came to $1.8 million, an operating margin of -89.7%. Diluted earnings per share were -$0.05.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

TTM
Jun 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Revenue
9
-8.0%
2
-14.9%
2
-13.7%
2
-5.2%
2
+2.1%
2
-0.8%
2
+5.9%
2
-97.1%
2
+1.8%
Cost of revenue
4
+5.1%
1
+5.2%
1
+24.6%
1
-8.1%
1
+2.2%
1
-13.2%
1
-23.4%
1
-5.6%
1
-0.9%
Gross profit
5
-15.4%
1
-26.3%
1
-31.3%
1
-3.4%
1
+2.1%
2
+8.0%
2
+28.5%
1
+22.1%
1
+3.7%
Research and development
3
+1.1%
1
-1.7%
1
+26.0%
0
-7.6%
1
-18.6%
1
-26.1%
1
+7.4%
0
-53.6%
1
-9.0%
Selling, general and administrative
9
-41.6%
2
-13.9%
2
-46.5%
2
-48.9%
2
-47.0%
3
-45.7%
4
-23.7%
4
+3.3%
4
-5.3%
Operating expenses
12
-34.4%
3
-11.3%
3
-31.8%
3
-44.7%
3
-41.9%
3
-42.5%
5
-19.0%
5
-8.1%
5
-6.0%
Operating income
-7
+43.6%
-2
-1.4%
-2
+32.0%
-1
+62.6%
-2
+57.8%
-2
+58.8%
-3
+31.2%
-3
+17.0%
-4
+9.0%
Pretax income
—
—
1
—
—
—
—
—
—
Net income
-10
-5.8%
-2
+9.2%
1
+136.5%
-3
-142.7%
-5
-37.9%
-3
+24.5%
-2
+60.0%
-1
+55.1%
-4
+24.6%
Basic EPS
-0.24
+43.5%
-0.05
+28.6%
0.02
+122.2%
-0.08
+5.0%
-0.13
+43.5%
-0.07
+75.0%
-0.09
+76.9%
-0.08
+72.0%
-0.23
+52.1%
Diluted EPS
-0.24
+43.5%
-0.05
+28.6%
-0.05
+44.4%
-0.08
+5.0%
-0.13
+43.5%
-0.07
+75.0%
-0.09
+76.9%
-0.08
+72.0%
-0.23
+52.1%
Weighted average shares, basic
42
+87.3%
44
+24.4%
43
+101.4%
43
+155.5%
36
+136.2%
36
+184.1%
22
+82.3%
17
+60.6%
15
+57.6%
Weighted average shares, diluted
42
+87.3%
44
+24.4%
46
+112.0%
43
+155.5%
36
+136.2%
36
+184.1%
22
+82.3%
17
+60.6%
15
+57.6%
Margins
Gross margin
58.78%
55.28%
54.45%
64.54%
60.00%
63.81%
68.45%
63.39%
60.04%
Operating margin
-80.75%
-89.69%
-112.00%
-57.63%
-68.50%
-75.29%
-142.17%
-146.06%
-165.88%
Pretax margin
—
—
34.37%
—
—
—
—
—
—
Profit margin
-117.07%
-118.28%
34.37%
-151.21%
-212.23%
-110.90%
-81.31%
-59.09%
-157.16%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as
AWHL (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Austin, TX
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
926617
Former names
VERMILLION, INC. (until Jun 10, 2020); CIPHERGEN BIOSYSTEMS INC (until Aug 17, 2007)

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.